Table S1 Clinical features of the study population

Characteristics	Value
Histology, %	
Adenocarcinoma	72
Squamous cell carcinoma	14
Other	14
Age at diagnosis, years	
Mean ± SD	69±10
Sex, %	
Female	41
Male	59
ECOG stage at diagnosis, %	
0 – fully active	34
1 – restricted in strenuous activity	48
2 – restricted in work activity	13
3 – capable of limited self care	4
4 – completely disabled	1
Symptoms at diagnosis, %	
None	29
Dyspnea	31
Cough	65
Hemoptysis	6
Weight loss	8
Neurological symptoms/signs	6
Pain	24
Other	8
Pulmonary function test, %	
FEV1 <1 L	2
Smoking History, %	
Never	22
Former	48
Current	30
Pack years, mean ± SD	35±22
Professional risk, %	
Any professional hazard exposure	33
Stage, %	
I	17
II	11
III	21
IV	51
Staging, %	
PET-CT 18 FDG	17
Total body CT	29.4
PET-CT 18 FDG + Total body CT	48
Other	0.6
None	5
Diagnostic procedure, %	
CT guided transthoracic biopsy	21
US guided transthoracic biopsy	1
Thoracentesis	1
Medical thoracoscopy	2
Bronchial biopsy	13
Transbronchial biopsy	7
EBUS-TBNA	18
Lung surgery	33
Other*	4

*Other, metastasectomy.

Table S2 The co-occurring molecular aberrancies according to molecular tests

Aberrant Oncogene	ALK	ROS1	RET	MET	EGFR	KRAS	BRAF
ALK	17	1	0	0	0	3	0
ROS1	1	4	0	0	0	1	0
RET	0	0	9	0	0	0	0
MET	0	0	0	23	1	4	1
EGFR	0	0	0	1	214	2	2
KRAS	3	1	0	4	2	300	6
BRAF	0	0	0	1	2	6	37
Total	21	6	9	29	219	316	46